Gan & Lee Pharmaceuticals. (SHA:603087)

Market Cap	40.91B +15.3%
Revenue (ttm)	3.95B +13.7%
Net Income	1.02B +23.3%
EPS	1.73 +22.7%
Shares Out	595.20M
PE Ratio	39.68
Forward PE	26.64
Dividend	1.00 (1.45%)
Ex-Dividend Date	May 29, 2026

Volume	9,198,124
Open	67.06
Previous Close	67.90
Day's Range	66.66 - 69.49
52-Week Range	51.51 - 82.25
Beta	0.27
Analysts	Strong Buy
Price Target	72.50 (+5.49%)
Earnings Date	Aug 26, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insu...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 5,309
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.

Analyst Summary

According to 3 analysts, the average rating for 603087 stock is "Strong Buy." The 12-month stock price target is ¥72.50, which is an increase of 5.49% from the latest price.

Price Target

¥72.50

(5.49% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error